Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead

Showing 15 posts of 239 posts found.

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

April 18, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Genentech, Gilead, HIV, MS, Novartis, kidney disease, pharma

This week was a good one for clinical trials and a bad one for employees after both Gilead and GSK …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

April 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior

This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile …

News
gilead-sciences

Gilead to lay off one fifth of sales force

April 11, 2019
Sales and Marketing Gilead, Jobs, Letairis, Ranexa, redundancy, sales

Gilead Sciences is preparing to lay off around a fifth of its salesforce in anticipation for the expiry of patents …

News

Gilead accused of ripping off US taxpayers

March 28, 2019
Medical Communications, Sales and Marketing CDC, Gilead, HIV, PrEP, Truvada, US government, patents

Gilead have been accused of ‘ripping off’ US taxpayers after the firm was revealed to have generated $3 billion in …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

March 8, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Biogen, Gilead, HIV, Novartis, Scott Gottlieb, top 10

HIV hit the headlines this week after it was announced that a British man known only as the ‘London Patient’ …

News
gilead-sciences

Gilead’s Biktarvy maintains HIV suppression for 48 weeks in children and adolescents

March 7, 2019
Research and Development Biktarvy, Gilead, HIV, pharma

Gilead has lifted the curtain on new Phase 2/3 efficacy data for Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 …

News
scotland

Gilead’s CAR-T therapy Yescarta rejected for NHS use in Scotland

February 12, 2019
Manufacturing and Production, Sales and Marketing CAR-T, Cancer, Gilead, NHS, Scotland, Yescarta, kite pharma

It’s bad news for Scottish patients living with aggressive forms of non-Hodgkin lymphoma (NHL) as it emerges that the Scottish …

News
gilead-sciences

Gilead shares drop 4% after failure of NASH drug to meet primary endpoint

February 12, 2019
Manufacturing and Production Gilead, Shares, fatty liver disease, nash, selonsertib

Gilead’s treatment for the progressive fatty liver disease, NASH, has failed to meet its primary goal in a phase 3 …

News
gilead-sciences

Gilead inks $1.8 bn deal with immuno-oncology biotech Agenus

December 21, 2018
Medical Communications Agenus, Gilead, Lexington, Massachusetts, USA, immuno-oncology, oncology

California-based firm Gilead Sciences and Massachusetts-based immuno-oncology biotech Agenus have announced that they have entered into a partnership focused on …

News
8643990124_7c11fee008_z

Gilead and Scholar Rock collaborate on fibrosis in deal worth more than $80m

December 20, 2018
Business Services, Research and Development Califonia, Gilead, Scholar Rock, USA, fibrosis

California-based antiviral drugs specialist Gilead Sciences has entered into a strategic partnership with Cambridge, Massachusetts-based biotech Scholar Rock as part …

News
82958bfc7df1311fd17a008495fc-1456375

Pharma in 2018: Looking back, looking forward

December 18, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2018, Alligator Bioscience, Eisai, Gilead, Mundipharma, pharma

2018 has been a year characterised by uncertainty, but also significant leaps in research, access, and industry deals. With 2019 …

Feature
pharmafocus_dec_2018_cover

The December issue of Pharmafocus is available to read online now!

December 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eisai, GSK, Gilead, Mundipharma, Pharmafocus, mesothelioma, pharma

The December edition of Pharmafocus is live and available to read online now!Brexit continues to dominate the headlines inside and …

News

Gilead names Roche veteran Daniel O’Day as new CEO

December 10, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Gilead, Roche, appointment

Almost half a year since it was revealed that Gilead’s Dr John Milligan would be stepping down from his role …

News
gilead-sciences

NICE give go-ahead to Gilead’s Yescarta for adults with lymphoma

December 7, 2018
Medical Communications Cancer, Cost, Gilead, NHS, NICE, Yescarta, access

The NHS cost effectiveness body NICE has approved Gilead’s Yescarta for treatment of come adults with lymphoma. Gilead’s treatment will …

News
gilead-sciences

Gilead’s CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma

December 3, 2018
Research and Development, Sales and Marketing ASH 2-18, CAR-T, Cancer, Gilead, Yescarta, leukaemia, pharma

Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024